


REMARKS

By the subject Amendment, Applicants have amended the Specification, cancelled Claim 4 without prejudice and added Claim 8. Accordingly, Claims 1 to 3 and 5 to 8 are presently pending herein. Claims 1 and 8 are presented in independent form. Claims 1 to 3 and 5 to 7 have been withdrawn from consideration by the Examiner. Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

The specification beginning at page 3 (line 22) was amended by the insertion of the following paragraph:

The present invention also provides for a method of selectively targeting protein receptors as found in a cell, the method consisting of the steps of preparing a molecule of formula I, prodrugs thereof or a pharmaceutically acceptable salt thereof:



formula I

wherein R is selected from the group consisting of: *t*-butyl, *i*-propyl and *sec*-butyl; testing the molecules against various cell receptors; and isolating effect and responsiveness of the molecule against the cell receptors.

Support for this amendment to the Specification can be found in Claim 4 of the Specification as originally filed.

Claim 8, as presented in the Amendment dated January 22, 2003 was objected to as not being drawn to a ligand receptor assay. The Examiner stated that prior Claim 8 is directed to a tumor cell line alkylation assay that constitutes a new, non-elected class. Since the Amendment dated January 22, 2003, has been held non-responsive it is believed that it has not been entered. Accordingly, the amendments to the Specification and Claims presented in the Amendment dated January 22, 2003, are believed not to have been entered.

Claim 8 as presented herein overcomes the Examiner's reasons for holding the prior amendment non-responsive. Applicants respectfully submit that this amendment is permissible since the subject matter of Claim 8 as presented herein was part of the Specification as originally filed. Furthermore, in view of the 35 U.S.C. 112 rejections by the Examiner in the letter dated August 14, 2002, Applicants respectfully submit that Claim 8 is fully supported by the Specification as originally filed. More specifically, support for Claim 8 can be found on pages 15-19, as well as in Figure 1-6 of the specification as originally filed.

A marked up version showing amendments to the Specification and claims is provided in the attached "Marked up Version of Amendments." Changes are shown using underlines and strikeouts.


It is respectfully submitted that the present application is in condition for allowance and a notification to this effect is requested. It is believed that no fee is due for this submission. Should that determination be incorrect, however, the Examiner is hereby authorized to charge any deficiencies to our Deposit Account No. 13-2759, and notify the undersigned in due course. Should

the Examiner have any questions or wish to discuss further this matter, please contact the undersigned at the telephone number provided below.

Date:

4/30/03

Respectfully submitted,



James J. Merek
Attorney for Applicants
Reg. No. 32,158

MEREK, BLACKMON & VOORHEES, LLC
673 South Washington Street
Alexandria, Virginia 22314
(703) 684-5633


MARKED UP VERSION OF AMENDMENTS

The specification and claims have been amended as follows. Underlines indicate insertions.

Specification Amendment

At page 3, line 22 was amended by inserting the following paragraph:

-- The present invention also provides for a method of selectively targeting protein receptors as found in a cell, the method consisting of the steps of preparing a molecule of formula I, prodrugs thereof or a pharmaceutically acceptable salt thereof:



formula I


wherein R is selected from the group consisting of: *t*-butyl, *i*-propyl and *sec*-butyl; testing the molecules against various cell receptors; and isolating effect and responsiveness of the molecule against the cell receptors. --

Claim Amendments

Claim 4 has been cancelled without prejudice and Claim 8 has been added as follows:

8. (New) A method for targeting protein receptors as found in a human carcinoma cell line, said method consisting of the steps of:

i) preparing a molecule of formula I, prodrugs thereof or a pharmaceutically acceptable salt thereof:



formula I

wherein R is selected from the group consisting of *t*-butyl, *i*-propyl and *s*-butyl;

ii) incubating the human carcinoma cell line with the compound of formula I, to provide incubated cells;

iii) detecting binding of the protein receptors with the molecule of formula I by measuring inactivation of the protein.